New Antibody-Drug conjugate STRO-002 tested in advanced cancers

NCT ID NCT06238687

Completed Disease control Sponsor: Tasly Pharmaceutical Group Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called STRO-002 in 19 Chinese adults with advanced ovarian, endometrial, or other solid tumors that had not responded to prior treatments. STRO-002 is an antibody-drug conjugate, meaning it combines a targeted antibody with a chemotherapy drug to deliver the drug directly to cancer cells. The main goals were to check safety, side effects, and how the drug moves through the body, as well as to get an early look at whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STRO-002 (an antibody-drug conjugate that combines a targeted antibody with a chemotherapy drug)
What this could lead to: If successful, this could point toward a new treatment option for advanced ovarian, endometrial, and other solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 19 participants, so results may not apply to larger populations. The drug may cause side effects or fail to shrink tumors effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer endometrial cancer fallopian tube cancer neoplasm non-small cell lung carcinoma ovarian carcinoma primary peritoneal carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOPLASM MALIGNANT

Contacts and locations

Locations

West China Hospital of Sichuan University

Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.